A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
Aleksandr Lazaryan, Stephanie Lee, Mukta Arora, Jongphil Kim, Brian Christopher Betts, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Hien Liu, Mohamed A Kharfan-Dabaja, Frederick L Locke, Rebecca Gonzalez, Michael D Jain, Marco L Davila, Lia Elena Perez, Asmita Mishra, Ariel Perez Perez, Karlie Balke, Ernesto Ayala, Leonel Ochoa, Omar Castaneda Puglianini, Rawan Faramand, Melissa Alsina, Hany Elmariah, Michael L Nieder, Hugo Fernandez, Claudio Anasetti, Joseph A Pidala, Aleksandr Lazaryan, Stephanie Lee, Mukta Arora, Jongphil Kim, Brian Christopher Betts, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Hien Liu, Mohamed A Kharfan-Dabaja, Frederick L Locke, Rebecca Gonzalez, Michael D Jain, Marco L Davila, Lia Elena Perez, Asmita Mishra, Ariel Perez Perez, Karlie Balke, Ernesto Ayala, Leonel Ochoa, Omar Castaneda Puglianini, Rawan Faramand, Melissa Alsina, Hany Elmariah, Michael L Nieder, Hugo Fernandez, Claudio Anasetti, Joseph A Pidala
Abstract
Standard initial therapy of chronic graft vs. host disease (cGVHD) with glucocorticoids results in suboptimal response. Safety and feasibility of therapy with ofatumumab (1000 mg IV on days 0 and 14) and prednisone (1 mg/kg/day) was previously established in our phase I trial (n = 12). We now report the mature results of the phase II expansion of the trial (n = 38). The overall NIH severity of cGVHD was moderate (63%) or severe (37%) with 74% of all patients affected by the overlap subtype of cGVHD and 82% by prior acute cGVHD. The observed 6 month clinician-reported and 2014 NIH-defined overall response rates (ORR = complete + partial response [CR/PR]) of 62.5% (1-sided lower 90% confidence interval=51.5%) were not superior to pre-specified historic benchmark of 60%. Post-hoc comparison of 6 month NIH response suggested benefit compared to more contemporaneous NIH-based benchmark of 48.6% with frontline sirolimus/prednisone (CTN 0801 trial). Baseline cGVHD features (organ involvement, severity, initial immune suppression agents) were not significantly associated with 6-month ORR. The median time to initiation of second-line therapy was 5.4 months (range 0.9-15.1 months). Failure-free survival (FFS) was 64.2% (95% CI 46.5-77.4%) at 6 months and 53.1% (95% CI 35.8-67.7%) at 12 months, whereas FFS with CR/PR at 12 months of 33.5% exceeded a benchmark of 15% in post-hoc analysis, and was associated with greater success in steroid discontinuation by 24 months (odds ratio 8 (95% CI 1.21-52.7). This single-arm phase II trial demonstrated acceptable safety and potential efficacy of the upfront use of ofatumumab in combination with prednisone in cGVHD. This trial was registered at www.clinicaltrials.gov as #NCT01680965.
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Figures
References
- Arora M, Cutler CS, Jagasia MH, et al. . Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(3):449-455.
- Arai S, Arora M, Wang T, et al. ; Graft-vs-Host Disease Working Committee of the CIBMTR . Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-274.
- Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114(1):7-19.
- Pidala J, Kurland B, Chai X, et al. . Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651-4657.
- Lee SJ, Nguyen TD, Onstad L, et al. . Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24(3):555-562.
- Pidala J, Martens M, Anasetti C, et al. . Factors associated with successful discontinuation of immune suppression after allogeneic hematopoietic cell transplantation. JAMA Oncol. 2020;6(1):e192974.
- Hamilton BK, Storer BE, Wood WA, et al. . Disability related to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2020;26(4):772-777.
- Arai S, Jagasia M, Storer B, et al. . Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242-4249.
- Inamoto Y, Storer BE, Lee SJ, et al. . Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood. 2013;121(12):2340-2346.
- Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood. 2019;133(11):1191-1200.
- Arora M, Wagner JE, Davies SM, et al. . Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(5):265-273.
- Gilman AL, Schultz KR, Goldman FD, et al. . Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children’s Oncology Group study. Biol Blood Marrow Transplant. 2012;18(1):84-91.
- Martin PJ, Storer BE, Rowley SD, et al. . Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074-5082.
- Sullivan KM, Witherspoon RP, Storb R, et al. . Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546-554.
- Carpenter PA, Logan BR, Lee SJ, et al. ; BMT CTN . A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica. 2018;103(11):1915-1924.
- Inamoto Y, Flowers ME, Sandmaier BM, et al. . Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124(8):1363-1371.
- Cooke KR, Luznik L, Sarantopoulos S, et al. . The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211-234.
- Arai S, Pidala J, Pusic I, et al. . A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res. 2016;22(2):319-327.
- Cutler C, Miklos D, Kim HT, et al. . Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108(2):756-762.
- Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C, Mohty M, Kumar A. Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2009;15(9):1005-1013.
- Kharfan-Dabaja MA, Cutler CS. Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol. 2011;93(5):578-585.
- Cutler C, Kim HT, Bindra B, et al. . Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510-1517.
- Sarantopoulos S, Blazar BR, Cutler C, Ritz J. B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(1):16-23.
- Arai S, Sahaf B, Narasimhan B, et al. . Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119(25):6145-6154.
- Solomon SR, Sizemore CA, Ridgeway M, et al. . Safety and efficacy of rituximab-based first line treatment of chronic GVHD. Bone Marrow Transplant. 2019;54(8):1218-1226.
- Solomon SR, Sizemore CA, Ridgeway M, et al. . Corticosteroid-free primary treatment of chronic extensive graft-versus-host disease incorporating rituximab. Biol Blood Marrow Transplant. 2015;21(9):1576-1582.
- Pidala J, Kim J, Betts BC, et al. . Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. Biol Blood Marrow Transplant. 2015;21(6):1074-1082.
- Jagasia MH, Greinix HT, Arora M, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.
- Lee SJ, Wolff D, Kitko C, et al. . Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015;21(6):984-999.
- Pidala J, Chai X, Martin P, et al. . Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium. Biol Blood Marrow Transplant. 2013;19(6):967-972.
- Martin PJ, Storer BE, Inamoto Y, et al. . An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. Blood. 2017;130(3):360-367.
- Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics. 1985;41(3):741-744.
- Pokhrel A, Dyba T, Hakulinen T. A Greenwood formula for standard error of the age-standardised relative survival ratio. Eur J Cancer. 2008;44(3):441-447.
- Miklos D. Ibrutinib vs. placebo in combination with corticosteroids in patients with new-onset chronic graft vs. host disease: results from the randomized, double-blind, phase 3 INTEGRATE study. Paper presented at the EHA meeting, 2021.
- Identifier NCT02959944: Ibrutinib in combination with corticosteroids vs placebo in combination with corticosteroids in participants with new onset chronic graft versus host disease (cGVHD) (iNTEGRATE). . Accessed 8 September 2021.
- Williams KM, Inamoto Y, Im A, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021;27(6):452-466.
- Kitko CL, Pidala J, Schoemans HM, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. Transplant Cell Ther. 2021;27(7):545-557.
- Pidala J, Kitko C, Lee SJ, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021;27(8):632-641.
- DeFilipp Z, Couriel DR, Lazaryan A, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease: III. The 2020 Treatment of Chronic GVHD Report. Transplant Cell Ther. 2021;27:729-737.
- Malard F, Labopin M, Yakoub-Agha I, et al. . Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study. Blood. 2017;130(20):2186-2195.
Source: PubMed